HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models

Both PD1/PD-L1 and CD47 blockades have demonstrated limited activity in most subtypes of NHL save NK/T-cell lymphoma. The hemotoxicity with anti-CD47 agents in the clinic has been speculated to account for their limitations. Herein we describe a first-in-class and rationally designed bispecific anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Hang, Zhang, Faming, Wang, Jingjing, Xiong, Lingxin, An, Xiaoyu, Tu, Xiaolong, Chen, Cen, Wang, Yueying, Mao, Binchen, Guo, Sheng, Ju, Cunxiang, He, Xiangfei, Sun, Ruilin, Zhang, Lei, O’Connor, Owen A., Li, Qi-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070465/
https://www.ncbi.nlm.nih.gov/pubmed/37012357
http://dx.doi.org/10.1038/s41598-023-32547-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070465/
https://www.ncbi.nlm.nih.gov/pubmed/37012357
http://dx.doi.org/10.1038/s41598-023-32547-y

Ejemplares similares